RESTASIS is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca (dry eye syndrome). Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.